New Skin Cream Approved for Psoriasis
Jan. 13, 2006 -- The FDA has approved the first skin cream to combine two popular psoriasis therapies in a single, once-a-day treatment.
More than 4.5 million people suffer from psoriasis, which is a chronic skin disease that can cause patches of itchy, scaly, and inflamed skin. It is not a contagious disease. Although there isn't a cure for the disease, several treatments can keep it under control.
Taclonex combines two widely used psoriasis treatments: a corticosteroid to treat inflammation and a form of vitamin D to control cell growth.
The FDA based its approval on studies that showed the skin cream significantly improved mild to severe cases of psoriasis.
Taclonex was developed in Denmark in 2001 and has been used in 63 countries under the names Dovobet and Daivobet.
Warner Chilcott will market Taclonex in the U.S. and expects to have the drug available in pharmacies by June 2006, the company says in a news release.
More than 4.5 million people suffer from psoriasis, which is a chronic skin disease that can cause patches of itchy, scaly, and inflamed skin. It is not a contagious disease. Although there isn't a cure for the disease, several treatments can keep it under control.
Taclonex combines two widely used psoriasis treatments: a corticosteroid to treat inflammation and a form of vitamin D to control cell growth.
The FDA based its approval on studies that showed the skin cream significantly improved mild to severe cases of psoriasis.
Taclonex was developed in Denmark in 2001 and has been used in 63 countries under the names Dovobet and Daivobet.
Warner Chilcott will market Taclonex in the U.S. and expects to have the drug available in pharmacies by June 2006, the company says in a news release.
Source...